The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability. In additional aspects, the present disclosure provides novel methods of synthesizing novel crystalline fine particle form of PRX-3140 potassium salt, preparing crystalline PRX-3140 potassium salt particle delivery systems (PDS), and preparing novel final dosage forms (FDF) of crystalline fine particle PRX-3140 potassium salt. In certain aspects, the present disclosure provides novel crystalline forms of fine particle PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms.

The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability. In additional aspects, the present disclosure provides novel methods of synthesizing novel crystalline fine particle form of PRX-3140 potassium salt, preparing crystalline PRX-3140 potassium salt particle delivery systems (PDS), and preparing novel final dosage forms (FDF) of crystalline fine particle PRX-3140 potassium salt. In certain aspects, the present disclosure provides novel crystalline forms of fine particle PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms.

A novel compound is provided. A light-emitting element with high emission efficiency and a long lifetime is provided. The compound is an organic compound that includes a benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton (General Formula (G0)). The 2-position of the benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton has a substituent and the 6- to 9-positions of the skeleton have at least one substituent. Any one of the substituents bonded to the 6- to 9-positions is bonded to the benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton via a phenylene group. A light-emitting element including the compound is provided.

Methods are disclosed of designing antibodies for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,000. The method comprises preparing a first antibody that binds to the small molecule, and preparing a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a predetermined portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.

The present invention is based, in part, on the discovery that the polymeric materials described herein produce polyurethane copolymers with advantageous optical properties. In particular embodiments, polyurethane copolymers comprise repeating units of isosorbide and a difunctional linker where the difunctional linkers can be diisocyanate, dithiocyanate, dicarboxylic acid, and other monomers. Some of the advantageous optical properties of these polymeric materials include a refractive index of about 1.5 and an Abbe value of at least about 50. Also described are methods for producing these polyurethane copolymers.

The present invention is based, in part, on the discovery that the polymeric materials described herein produce polyurethane copolymers with advantageous optical properties. In particular embodiments, polyurethane copolymers comprise repeating units of isosorbide and a difunctional linker where the difunctional linkers can be diisocyanate, dithiocyanate, dicarboxylic acid, and other monomers. Some of the advantageous optical properties of these polymeric materials include a refractive index of about 1.5 and an Abbe value of at least about 50. Also described are methods for producing these polyurethane copolymers.